Therefore, these results indicated that CNN1 has a promising anticancer activity and as a potential lead compound to the development of a new treatment for CML patients who fail their TKI therapy due to intolerance and/or developed resistance, mainly in refractory disease advantage stages. This evidence concerns the gene CNN1 and chronic myelogenous leukemia, BCR-ABL1 positive.